|
|
ACR Business Meeting and Late-Breaking Abstracts
Session Type: ACR Late Breaking Abstracts
Tuesday, October 20, 2009: 2:00 PM-4:00 PM
204 B (Pennsylvania Convention Center)
| Moderator: |
Susan Manzi, MD, MPH, University of Pittsburgh
|
Talks:
4:30 PM
Belimumab, a BLyS-Specific Inhibitor, Reduced Disease Activity, Flares and Prednisone Use in Patients with Active SLE: Efficacy and Safety Results From the Phase 3 BLISS-52 Study
S. Navarra, U of Sto Tomas Hosp, Mla, Philippines;
R. Guzman, MD;
A. Gallacher, MD, HBBA;
R.A. Levy, M.D., Univ do Estado do Rio de Janeiro;
E.K. Li, MD, Chinese U of HK;
M. Thomas, M.D., Kerala Inst of Med Sci;
R. Jimenez, M.D., Hosp Dr Gustavo Fricke;
M. Leon, M.D., Inst de Ginec y Rep;
S. Hall, MD, Emeritus Res-Cabrini Hosp;
J.L. Lan, MD, Veterans Gen Hosp;
E. Nasonov, M.D., Institute of Rheumatology;
C. Tanasescu, Spitalul Clin Colentina;
H.-Y. Kim, Catholic U of Korea St Mary's Hosp;
L. Pineda, M.D., HGS;
Z.J. Zhong, PhD, HGS;
W. Freimuth, M.D., HGS;
M. A. Petri, MD, MPH, Johns Hopkins U;
BLISS-52 Study Group
4:45 PM
Treatment of Rheumatoid Arthritis (RA) with An Oral Syk Kinase Inhibitor: A 6 Month Randomized Placebo Controlled Phase 2b Study in Patients with Active RA On Chronic Methotrexate
Michael Weinblatt, MD, Brigham & Women's Hosp;
Arthur Kavanaugh, MD, UCSD;
Mark Genovese, MD, Stanford University;
Elliott Grossbard, MD, Rigel Pharma;
Daniel Magilavy, MD, Rigel Pharma
5:00 PM
An Oral Syk Kinase Inhibitor in the Treatment of Rheumatoid Arthritis(RA): A 3 Month Randomized Placebo Controlled Phase 2 Study in Patients with Active RA Who Had Failed Biologic Agents
Mark C. Genovese, MD, Stanford University;
Arthur Kavanaugh, MD, UCSD;
Charles Peterfy, MD, PhD, SYNARC, Inc;
Daniel Magilavy, MD, Rigel Pharmaceuticals
5:15 PM
Canakinumab (ACZ885) Vs. Triamcinolone Acetonide for Treatment of Acute Flares and Prevention of Recurrent Flares in Gouty Arthritis Patients Refractory to or Contraindicated to NSAIDs and/or Colchicine
Alexander So, MBBCh, PhD, CHU Vaudois, University of Lausanne;
Marc De Meulemeester;
Talha Shamim, Heartland Clinical Research;
Andrey Pikhlak, MD, PhD, Moscow State University of Medicine and Dentistry;
A. Eftal Yücel, MD, MSc, Baskent University;
Udayasankar Arulmani, PhD, Novartis Pharma AG;
Dominik Richard, PhD, Novartis Pharma AG;
Valda Murphy, Novartis Pharma AG;
Peter Sallstig, MBA, MD, Novartis Pharma AG;
Naomi Schlesinger, MD, UMDNJ-Robert Wood Johnson Medical School
5:30 PM
Golimumab Inhibits Progression of Radiographic Damage in Patients with Psoriatic Arthritis: 52 Week Results From the GO-REVEAL Study
A. Kavanaugh, MD, University of California at San Diego;
D. van der Heijde, MD, PhD, Leiden U Med Ctr;
D. Gladman, FRCP, FRCP(C), FRCPC, MD, Toronto Western Hosp;
P. Mease, MD, Swedish Med Ctr/U of Washington;
I. McInnes, FRCP, PhD, U of Glasgow;
G.G. Krueger, MD, U of Utah Hlth Sciences Ctr;
W. Xu, PhD, Centocor R&D, Inc;
M. U. Rahman, MD, PhD, Centocor R&D, Inc/U of Penn School of Med;
J. Zrubek, MD, Centocor R&D, Inc;
A. Baratelle, Centocor R&D, Inc;
A. Beutler, MD, Centocor R&D, Inc
5:45 PM
In Early RA with Insufficient Response to MTX, the Addition of Anti-TNF Results in Less Radiological Progression Over 24 Months Than the Addition of Conventional DMARDs: Results From the SWEFOT Trial
Ronald F. van Vollenhoven, MD, PhD, The Karolinska Institute and Karolinska University Hospital;
Kristina Albertsson, MD, Department of Rheumatology, Karolinska University Hospital;
Kristina Forslind, MD, PhD, Department of Rheumatology, Helsingborgs Hospital;
P. Geborek, MD, PhD, Dept of Clinical Sciences, Lund, Section of Rheumatology, Lund University;
Sofia Ernestam, Karolinska University Hospital;
Ingemar F. Petersson, PhD, Musculoskeletal Research Center;
Johan Bratt, MD, PhD, Karolinska Univ Hosp Huddinge;
SWEFOT study group
|
![[Visit Client Website]](/img/acr/banner_2009.gif)
Search
Print Page
Browse by Day: 
